Emergency of vancomycin-resistant Enterococcus infections in a teaching hospital in Chile;Emergencia de infecciones por Enterococcus sp resistente a vancomicina en un hospital universitario en Chile

Revista Chilena de Infectologia

Volumn 24, Issue 6, 2007, Pages 462-471

  Fica Cubillos, Alberto ^a   Jemenao P , María Irene ^b   Bilbao V , Paola ^b   Ruiz R , Gloria ^b   Sakurada Z , Andrea ^b   De Arce O , Edith Pérez ^b   Zúñiga B , Isabel ^b   Gompertz G , Macarena ^b  

^a HOSPITAL CLÍNICO UNIVERSIDAD DE CHILE   (Chile)

^b UNIVERSITY OF CHILE   (Chile)

Author keywords

Clinical features; Emergency; Infection; Intestinal colonization; Outcomes; Treatment; Vancomycin resistant Enterococus

Indexed keywords

ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL INFECTION; CHILE; DRUG EFFECT; ENTEROCOCCUS; GENETICS; HUMAN; INCIDENCE; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; RISK FACTOR; STATISTICS; TEACHING HOSPITAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILE; ENTEROCOCCUS; GRAM-POSITIVE BACTERIAL INFECTIONS; HOSPITALS, TEACHING; HUMANS; INCIDENCE; MIDDLE AGED; RISK FACTORS; VANCOMYCIN RESISTANCE;

EID: 37449017586     PISSN: 07161018     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Lodise T P, McKinnon P S, Tam V H, Rybak M J. Clinical outcomes for patients with bacteriemia caused by vancomycin-resistant Enterococcus in a level 1 Trauma Center. Clin Infect Dis 2002; 34: 922-9.
2. Carmeli Y, Eliopoulos G, Mozaffari E, Samore M. Health and economic outcomes of vancomycin-resistant Enterococci. Arch Intern Med 2002; 162: 2223-8.
3. Juliet C. Estudio de susceptibilidad in vitro de Enterococcus spp. Rev Chil Infect 2002; 19 (Supl 2): S111-115
4. Chavers L S, Moser S A, Benjamín W H Jr, Banks S E, Steinbauer J R, et al. Vancomycin-resistant enterococci: 15 years and counting. J Hosp Infect 2003; 53: 159-71.
5. Clinical Laboratory Standard Institute. Performance Standards for Antimicrobial Susceptibility Testing. Fifteenth informational supplement. M100-S15. Vol. 25 No 1.
6. Clinical Laboratory Standard Institute. Performance Standards for Antimicrobial Susceptibility Testing; Sixteenth informational supplement. M100-S16. Vol 26 No 3.
7. Fica A, Luppi M, Olivares R, Brito L, Zilleruelo I, Muñoz L. Cumplimiento sobre las recomendaciones de uso y evaluación del impacto económico de un programa de uso restringido de imipenem-cilastatina. Rev Chil Infect 2006; 23: 307-15.
8. Marovac J, Campos M I. Enterococcus faecium resistente a vancomicina. Rev Méd Chile 2000; 128: 685-6.
9. Mella S, Sepúlveda M, Acosta P, Bello H, Domínguez M, González G, et al. Aislamiento de Enterococcus faecium resistente a vancomicina en el Hospital Clínico Regional de Concepción. Rev Chil Infect 2002; 19: 32-6.
10. Silva J, Asserella L, Bolados N, Herrera N, Leyton J. Resistencia a antimicrobianos en cepas de Enterococcus sp aisladas en hospitales del norte de Chile. Rev Chil Infect 2006; 23: 226-31.
11. Silva J, Loyola P, Galleguillos J, Rodríguez Y, Colque-Navarro P, Mollby R, et al. Prevalencia de enterococos resistentes a antibióticos en aguas servidas en el Norte de Chile. Rev Méd Chile 2005; 133: 1201-10.
12. D'Agata E M C, Gautam S, Green W K, Tang Y W. High rate of false-negative results of the rectal swab culture method in detection of gastrointestinal colonization with vancomycin-resistant Enterococci. Clin Infect Dis 2002; 34: 167-72.
13. Montecalvo M A, Shay D K, Patel P, Tacsa L, Maloney S A, Jarvis W R, Wormser G P. Bloodstream infections with vancomycin-resistant enterococci. Arch Intern Med 1996; 156: 1458-62.
14. Bonten M J M, Willems R, Weinstein R A. Vancomycin-resistant enterococci: why are they here, and where do they come from? Lancet Infect Dis 2001; 1: 314-25.
15. Peset V, Tallón P, Sola C, Sánchez E, Sarrión A, Pérez-Bellés C, et al. Epidemiological, microbiological, clinical, and prognostic factors of bacteremia caused by high-level vancomycin-resistant Enterococcus species. Eur J Clin Microbiol Infect Dis 2000; 19: 742-9.
16. Carmeli Y, Samore M H, Huskins C. The association between antecedent vancomycin treatment and hospital-acquired vancomycin-resistant Enterococci. A meta-analysis. Arch Intern Med 1999; 159: 2461-8.
17. th Ed. Williams & Wilkins, Baltimore, 1996. p 453-501.
18. Bhavnani S M, Drake J A, Forrest A, Deinhart J A, Jones R N, Biedenbach D J, et al. A nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia. Diagn Microb Infect Dis 2000; 36: 145-58.
19. Moellering R C, Linden P K, Reinhardt J, Blumberg E A, Bompart F, Talbot G H. The efficacy and safety of quinupristin/ dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. Synercid Emergency-Use Study Group. J Antimicrob Chemother 1999; 44: 251-61.
20. Moellering R C. Linezolid: The first oxazolidinone antimicrobial. Ann Intern Med 2003; 138: 135-42.
21. Hayden M K, Koening G I, Trenholme G M. Bactericidal activities of antibiotics against vancomycin-resistant Enterococcus faecium blood isolates and synergistic activities of combinations. Antimicrob Agents Chemother 1994; 38: 1225-9.
22. Martino P, Venditti M, Micozzi A, Brandimarte C, Gentile G, Santini C, et al. Teicoplanin in the treatment of Gram-positive-bacterial endocarditis. Antimicrob Agents Chemother 1989; 33: 1329-34.
23. Schmit J L. Efficacy of teicoplanin for enterococcal infections: 63 cases and review. Clin Infect Dis 1992; 15: 302-6.